Alexei Zelenev1, Jianghong Li2, Alyona Mazhnaya3, Sanjay Basu4, Frederick L Altice5. 1. Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, Yale School of Medicine, New Haven, CT, USA. Electronic address: alexei.zelenev@yale.edu. 2. Institute for Community Research, Hartford, CT, USA. 3. ICF Alliance for Public Health, Kyiv, Ukraine; Department of Health, Behavior & Society, Johns Hopkins Bloomberg School of Public Health, MD, USA. 4. Stanford University School of Medicine, Stanford, CA, USA. 5. Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, Yale School of Medicine, New Haven, CT, USA; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA; Centre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Abstract
BACKGROUND: Chronic infections with hepatitis C virus (HCV) and HIV are highly prevalent in the USA and concentrated in people who inject drugs. Treatment as prevention with highly effective new direct-acting antivirals is a prospective HCV elimination strategy. We used network-based modelling to analyse the effect of this strategy in HCV-infected people who inject drugs in a US city. METHODS: Five graph models were fit using data from 1574 people who inject drugs in Hartford, CT, USA. We used a degree-corrected stochastic block model, based on goodness-of-fit, to model networks of injection drug users. We simulated transmission of HCV and HIV through this network with varying levels of HCV treatment coverage (0%, 3%, 6%, 12%, or 24%) and varying baseline HCV prevalence in people who inject drugs (30%, 60%, 75%, or 85%). We compared the effectiveness of seven treatment-as-prevention strategies on reducing HCV prevalence over 10 years and 20 years versus no treatment. The strategies consisted of treatment assigned to either a randomly chosen individual who injects drugs or to an individual with the highest number of injection partners. Additional strategies explored the effects of treating either none, half, or all of the injection partners of the selected individual, as well as a strategy based on respondent-driven recruitment into treatment. FINDINGS: Our model estimates show that at the highest baseline HCV prevalence in people who inject drugs (85%), expansion of treatment coverage does not substantially reduce HCV prevalence for any treatment-as-prevention strategy. However, when baseline HCV prevalence is 60% or lower, treating more than 120 (12%) individuals per 1000 people who inject drugs per year would probably eliminate HCV within 10 years. On average, assigning treatment randomly to individuals who inject drugs is better than targeting individuals with the most injection partners. Treatment-as-prevention strategies that treat additional network members are among the best performing strategies and can enhance less effective strategies that target the degree (ie, the highest number of injection partners) within the network. INTERPRETATION: Successful HCV treatment as prevention should incorporate the baseline HCV prevalence and will achieve the greatest benefit when coverage is sufficiently expanded. FUNDING: National Institute on Drug Abuse.
BACKGROUND:Chronic infections with hepatitis C virus (HCV) and HIV are highly prevalent in the USA and concentrated in people who inject drugs. Treatment as prevention with highly effective new direct-acting antivirals is a prospective HCV elimination strategy. We used network-based modelling to analyse the effect of this strategy in HCV-infectedpeople who inject drugs in a US city. METHODS: Five graph models were fit using data from 1574 people who inject drugs in Hartford, CT, USA. We used a degree-corrected stochastic block model, based on goodness-of-fit, to model networks of injection drug users. We simulated transmission of HCV and HIV through this network with varying levels of HCV treatment coverage (0%, 3%, 6%, 12%, or 24%) and varying baseline HCV prevalence in people who inject drugs (30%, 60%, 75%, or 85%). We compared the effectiveness of seven treatment-as-prevention strategies on reducing HCV prevalence over 10 years and 20 years versus no treatment. The strategies consisted of treatment assigned to either a randomly chosen individual who injects drugs or to an individual with the highest number of injection partners. Additional strategies explored the effects of treating either none, half, or all of the injection partners of the selected individual, as well as a strategy based on respondent-driven recruitment into treatment. FINDINGS: Our model estimates show that at the highest baseline HCV prevalence in people who inject drugs (85%), expansion of treatment coverage does not substantially reduce HCV prevalence for any treatment-as-prevention strategy. However, when baseline HCV prevalence is 60% or lower, treating more than 120 (12%) individuals per 1000 people who inject drugs per year would probably eliminate HCV within 10 years. On average, assigning treatment randomly to individuals who inject drugs is better than targeting individuals with the most injection partners. Treatment-as-prevention strategies that treat additional network members are among the best performing strategies and can enhance less effective strategies that target the degree (ie, the highest number of injection partners) within the network. INTERPRETATION: Successful HCV treatment as prevention should incorporate the baseline HCV prevalence and will achieve the greatest benefit when coverage is sufficiently expanded. FUNDING: National Institute on Drug Abuse.
Authors: D A Rolls; G Daraganova; R Sacks-Davis; M Hellard; R Jenkinson; E McBryde; P E Pattison; G L Robins Journal: J Theor Biol Date: 2011-12-16 Impact factor: 2.691
Authors: Soumitri Barua; Robert Greenwald; Jason Grebely; Gregory J Dore; Tracy Swan; Lynn E Taylor Journal: Ann Intern Med Date: 2015-08-04 Impact factor: 25.391
Authors: Arthur Y Kim; Julian Schulze zur Wiesch; Thomas Kuntzen; Joerg Timm; Daniel E Kaufmann; Jared E Duncan; Andrea M Jones; Alysse G Wurcel; Benjamin T Davis; Rajesh T Gandhi; Gregory K Robbins; Todd M Allen; Raymond T Chung; Georg M Lauer; Bruce D Walker Journal: PLoS Med Date: 2006-12 Impact factor: 11.069
Authors: David A Rolls; Rachel Sacks-Davis; Rebecca Jenkinson; Emma McBryde; Philippa Pattison; Garry Robins; Margaret Hellard Journal: PLoS One Date: 2013-11-01 Impact factor: 3.240
Authors: Natasha K Martin; Peter Vickerman; Jason Grebely; Margaret Hellard; Sharon J Hutchinson; Viviane D Lima; Graham R Foster; John F Dillon; David J Goldberg; Gregory J Dore; Matthew Hickman Journal: Hepatology Date: 2013-08-26 Impact factor: 17.425
Authors: Asher J Schranz; Jessica Barrett; Christopher B Hurt; Carlos Malvestutto; William C Miller Journal: Curr HIV/AIDS Rep Date: 2018-06 Impact factor: 5.071
Authors: Meghan D Morris; Ali Mirzazadeh; Jennifer L Evans; Alya Briceno; Phillip Coffin; Judith A Hahn; Kimberly A Page Journal: Drug Alcohol Depend Date: 2019-02-27 Impact factor: 4.492
Authors: Hannah Fraser; Claudia Vellozzi; Thomas J Hoerger; Jennifer L Evans; Alex H Kral; Jennifer Havens; April M Young; Jack Stone; Senad Handanagic; Susan Hariri; Carolina Barbosa; Matthew Hickman; Alyssa Leib; Natasha K Martin; Lina Nerlander; Henry F Raymond; Kimberly Page; Jon Zibbell; John W Ward; Peter Vickerman Journal: Am J Epidemiol Date: 2019-08-01 Impact factor: 4.897